Hypogonadotropic hypogonadism

Indication for Follitropin alfa

Population group: Suitable for men, only adults (18 - 65 years old)
Therapeutic intent: Curative procedure

Follitropin alfa is indicated for the stimulation of spermatogenesis in men who have congenital or acquired hypogonadotropic hypogonadism with concomitant human chorionic gonadotropin (hCG) therapy.

For this indication, competent medicine agencies globally authorize below treatments:

150 IU three times a week

Route of admnistration


Defined daily dose

150 - 150 [iU]

Dosage regimen

From 150 To 150 [iU] once every 2 day(s)

Detailed description

Follitropin alfa should be given at a dose of 150 IU three times a week, concomitantly with hCG, for a minimum of 4 months. If after this period, the patient has not responded, the combination treatment may be continued; current clinical experience indicates that treatment for at least 18 months may be necessary to achieve spermatogenesis.

Active ingredient

In women, the most important effect resulting from parenteral administration of FSH is the development of mature Graafian follicles.

Read more about Follitropin alfa

Related medicines

Develop a tailored medication plan for your case, considering factors such as age, gender, and health history

Ask the Reasoner